What Is Semaglutide?
The most-studied single GLP-1 agonist — what it is and how it is handled.
Home › Comparisons › Semaglutide vs Tirzepatide
The single GLP-1 agonist vs the dual GIP/GLP-1 agonist — what actually separates them, in plain English.
Semaglutide and tirzepatide are the two most-studied GLP-1 research peptides, and they come up together constantly — usually with the question of how they actually differ. The short version comes down to one thing: how many receptors each one targets.
Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). That single difference is what separates them.
Semaglutide is a single agonist — it activates the GLP-1 receptor, the most-studied pathway in metabolic research. For the full picture, see our semaglutide overview.
Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP receptor, a second incretin pathway involved in insulin response. See our tirzepatide overview for more.
| Compound | Type | Receptors |
|---|---|---|
| Semaglutide | Single agonist | GLP-1 |
| Tirzepatide | Dual agonist | GLP-1 + GIP |
Targeting a second receptor does not automatically make one “better” than the other — each is its own compound with its own research profile, studied for different reasons. The number of receptors is a description of mechanism, not a ranking.
Both arrive as lyophilized (freeze-dried) powders and are handled the same way: keep the sealed vial cool, dry, and out of light; reconstitute with bacteriostatic water (see how to reconstitute peptides); then refrigerate the solution, where it stays stable for weeks.
Whichever you study, knowing exactly what is in the vial is everything. A reputable source provides a Certificate of Analysis (COA) showing third-party HPLC purity and mass-spec identity for that specific batch — see what is a COA.
We recommend Vital Chems for tested compounds and bacteriostatic water.